Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...

- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - ...

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis ...

UCSF researchers develop customizable SNIPR sensors that activate engineered cells only near tumors, promising precise cancer ...

Headquartered in Cambridge, the United Kingdom, Bicycle Therapeutics plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical ...

There are many reasons someone may get sick frequently, from your environment and lifestyle to genetics and underlying ...

Nicky, who goes by @nickyshairandbeauty on TikTok, is on a mission to raise awareness for the symptoms she thought were ...

First and only NMPA-approved treatment for patients with CIDP in China Second VYVGART Hytrulo indication approved in China November 11, 2024 – ...

Despite experiencing joint pain—especially in her hands—along with body aches, hot flushes and sleeplessness, Richardson dismissed these symptoms as "normal," until one day in June when she was unable ...

Initial trials using CAR T cells in patients with autoimmune disorders have shown encouraging results ... and innate immune cells - Applications to a growing list of autoimmune conditions and cancer ...

Akari Therapeutics, Plc (Nasdaq: AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces shareholder approval in connection with ...